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[Abstract] The protocol outlined represents a cost-effective, rapid and reliable method for the generation of high-titre viral pseudotype particles with the wild-type SARS-CoV spike protein on a lentiviral vector core using the widely available transfection reagent PEI. This protocol is optimized for transfection in 6-well plates; however it can be readily scaled to different production volumes according to application. This protocol has multiple benefits including the use of readily available reagents, consistent, high pseudotype virus production Relative Luminescence Units (RLU) titres and rapid generation of novel coronavirus pseudotypes for research into strain variation, tropism and immunogenicity/sero-prevalence.
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[Background] The production and use of pseudotyped viral particles (PV) is widely established for many viruses, and applications in the fields of serology, surveillance and vaccine development are manifold Carnell et al., 2015) . PVs have proven to be powerful tools to study the effects of viral envelope glycoprotein mutations on serological outcomes, viral tropism and immunogenicity studies especially when combined with epitope information. PVs are chimeric viral constructs in which the outer (surface) glycoprotein(s) of one virus is combined with the replication-defective viral 'core' of another virus. PV allow for accurate, sequence-directed, sensitive antibody neutralization assays and antiviral screening to be conducted within a low biosecurity facility and offer a safe and efficient alternative to wildtype virus use, making them exquisitely beneficial for many emerging RNA viruses of pandemic potential. Many of the published protocols require modification of the SARS spike glycoprotein and/or expensive transfection reagents (Temperton, 2009 ). The protocol presented here utilizes the full-length, noncodon-optimized spike protein in conjunction with the low-cost transfection reagent PEI, making this protocol widely applicable to many stakeholder laboratories. Figure 1 shows a cartoon of the lentiviral SARS-CoV PV production process directed by plasmid co-transfection. 2 www.bio-protocol.org/e2514 Timeline: Transfection-24 h.
1. 293T/17 cells should be subcultured into 6-well plates at a ratio that will deliver 70-90% confluence at the time of transfection. Typically seeding 4 x 10 5 cells per well will achieve this level of confluency. Example is shown in Figure 2 . 2. DMEM/10% FBS/1% P/S and Opti-MEM ® should be pre-warmed to 37 °C using a water bath or an incubator.
3. Prepare two labelled sterile 1.5 ml microcentrifuge tubes (tube 1 and tube 2) for each well of a 6-well plate which will be used for transfections. 12. Incubation step: Incubate the plate at 37 °C, 5% CO2 overnight (o/n). In our hands incubation times of between 12-16 h result in equivalent final PV production RLU titres.
Timeline: 12-16 h post transfection. 5 www 2514 13. Post o/n incubation the culture media on the cells should be carefully removed and 2 ml fresh DMEM/10% FBS/1% P/S added. Again, add media slowly to one side of the well to avoid cell detachment.
14. Incubate the 6-well plates at 37 °C 5% CO2 o/n for 32-36 h. 17. Optional step: Additional culture media may be added to cells to allow a second harvest 18-24 h later by adding further DMEM/10% FBS/1% P/S. In this case, extreme care must be taken in initial PV collection (step A15) to avoid damage to the cell monolayer. We have observed that cells in poor health after first harvest result in significantly lower PV production RLU titres upon second harvest. Figure 3) .
Note: A control pseudotype virus can be created by following the steps outlined above but omitting the pCAGGS-SARS-CoV spike construct. This produces particles that do not express a viral surface glycoprotein (Delta Env control,

B. Titration steps (Figure 3)
Note: Titration consists of transduction of reporter (in this case firefly luciferase) into target cells mediated by the viral glycoprotein expressed on the viral pseudotype (SARS-CoV spike).
Controls for titration are provided via the inclusion of 'cell only' and 'Delta Env' columns. Control for transduction can be provided via a PV bearing the Vesicular stomatitis virus G protein (VSV-G) which utilizes a ubiquitous receptor which results in high RLU titres in all cell lines tested.
6 www.bio-protocol.org/e2514 9. Incubate the plate for 48 h at 37 °C 5% CO2.
10. Read plate using Bright Glo TM luciferase assay system on a Glomax 96 luminometer (or equivalent).
C. Pseudotype based neutralisation assay (pMN)
Note: pMN is the Inhibition of PV mediated transduction via an antibody (or inhibitor) directed
against the SARS glycoprotein.
1. In a 96-well white plate add 50 µl of DMEM/10% FBS/1% P/S to rows B to H, columns 1-12.
2. Add known amount of antibody (example 5 µl HN and R sera in Figure 4 ) into wells of row A, columns 2-10 in a total volume of 100 µl DMEM/10% FBS/1% P/S. Add known amount (e.g., 5 µl) of positive and negative antisera into wells A11 and A12 as controls. 6. Centrifuge plate for 1 min at 800 x g (Rcf) to ensure no inhibitor or liquid is located on the walls of the well.
7. Using data obtained from the titration, calculate the amount of DMEM required to dilute your SARS-PV to obtain 1 x 10 6 RLU in 50 µl, with a total volume of 5 ml. For example with an RLU/ml of 1 x 10 8 , 1 ml of PV should be mixed with 4 ml of DMEM.
8. Mix this diluted PV solution using the multichannel pipette, and aliquot 50 µl into each well on the plate, with the exception of wells A6-A12 (cell only control). A1-A6 will serve as virus only control.
9. Centrifuge plate for 1 min at 800 x g (Rcf) to ensure no virus is left on the walls of the well. 12. Incubate the plate for 48 h at 37 °C 5% CO2.
13. Read plate using Bright Glo TM luciferase assay system on a Glomax 96 luminometer (or equivalent).
Data analysis
1. RLU readings are multiplied to RLU/ml by the dilution factor of each well (20x, 40x, 80x, 160x, 320x, 640x, 1,280x, 2,560x). The mean of all 8 RLU/ml values is used as the final value reported for that column in the titration step. A linear relationship should be observed between RLU values and PV dilution, with values decreasing by 50% after each 1:2 dilution.
Care should be taken to check this linear relationship before multiplication, as this inherently can lead to false positives despite lack of PV or working PV ( 2. Protocol read-out and titration results ( Figure 5 ). PV with no surface glycoprotein, VSV-G; PV with VSV-G on surface.
